Neurofibroma classification: Difference between revisions

Jump to navigation Jump to search
Line 81: Line 81:
* Deep
* Deep
* Associated with [[NF1]]
* Associated with [[NF1]]
* Diffuse involvement along a large nerve and its branches
* [[Diffuse]] involvement along a large [[nerve]] and its [[Branches of medicine|branches]]
* Mostly internal/ intraneural
* Mostly [[internal]]/ intraneural
* Can also involve small nerves and superficial skin
* Can also involve small [[nerves]] and [[superficial]] [[skin]]
* Have more [[connective tissue]]/extracellular matrix than cutaneous [[Neurofibroma|neurofibromas]], that separates the [[nerve fibers]]
* Have more [[connective tissue]]/[[extracellular matrix]] than [[cutaneous]] [[Neurofibroma|neurofibromas]], that separates the [[nerve fibers]]
* Gross enlargement of the nerve with nodular tumor development results in the gross pathologic appearance referred to as “bag of worms”
* [[Gross]] enlargement of the [[nerve]] with [[nodular]] [[tumor]] [[development]] results in the [[gross]] [[Pathological|pathologic]] [[appearance]] referred to as “bag of worms”
* Generally believed to be present at [[birth]] (congenital)
* Generally believed to be present at [[birth]] ([[congenital]])
* Disfiguring
* Disfiguring
* Affects function due to sheer size as well as neurovascular compromise
* Affects [[Function (biology)|function]] due to sheer size as well as [[Neurovascular bundle|neurovascular]] compromise
* Upto 5% risk of malignant transformation
* Upto 5% risk of [[malignant]] [[transformation]]
*Plexiform neurofibroma exhibits following features on T2-weighted MRI:
*[[Plexiform neurofibroma]] exhibits following [[Features (pattern recognition)|features]] on T2-weighted [[Magnetic resonance imaging|MRI]]:
**Target sign (low signal intensity centrally with a ring of high signal intensity peripherally)
**Target [[Sign (medicine)|sign]] (low [[Signal (biology)|signal]] [[intensity]] centrally with a ring of high [[Signal (biology)|signal]] [[intensity]] peripherally)
**Fascicular sign
**Fascicular [[Sign (medical)|sign]]
**May appear as a larger and more infiltrating mass with lobulated borders with inhomogeneous enhancement
**May [[Appearance|appear]] as a larger and more [[Infiltration (medical)|infiltrating]] [[mass]] with lobulated borders with inhomogeneous enhancement
|-
|-
| style="background:#DCDCDC;" align="center" + |'''[[Pigmented lesions|Pigmented]] [[neurofibroma]]'''  
| style="background:#DCDCDC;" align="center" + |'''[[Pigmented lesions|Pigmented]] [[neurofibroma]]'''  
|
|
* Neurofibroma with melanin-bearing pigmented cells, usually only appreciated microscopically
* [[Neurofibroma]] with [[melanin]]-bearing [[Pigmented Lesions|pigmented]] [[Cells (biology)|cells]], usually only appreciated [[Microscopic|microscopically]]
* Not considered a true subtype
* Not considered a true subtype
* No increased risk of malignant transformation
* No increased risk of [[Malignancy|malignan]]<nowiki/>t [[transformation]]
|}
|}



Revision as of 18:37, 27 April 2019

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma classification

CDC on Neurofibroma classification

Neurofibroma classification in the news

Blogs on Neurofibroma classification

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Neurofibroma may be classified into 5 subtypes: cutaneous/dermal/localized, localized intraneural, subcutaneous, diffuse, intramuscular, plexiform and pigmented neurofibroma. Plexiform neurofibromas may be further sub-classified into diffuse and nodular plexiform.

Classification

Neurofibroma may be classified into following subtypes:[1][2][3][4]

Types of neurofibromas Characteristics/Description
Cutaneous/Dermal/Localized/Sporadic neurofibroma (90%)
Localized Intraneural neurofibroma
Subcutaneous neurofibroma
Diffuse neurofibroma

(superficial)

Intramuscular neurofibroma
Plexiform neurofibroma

(deep)

Pigmented neurofibroma

Plexiform neurofibromas can be further subclassified into following:[5]

Types of neurofibromas Characteristics/Description
Diffuse Plexiform neurofibroma
Nodular Plexiform neurofibroma

References


Template:WikiDoc Sources